Persist AI is a TechBio services platform that combines AI/ML models, a high-throughput robotic Cloud Lab, and formulation scientists to accelerate pharmaceutical drug product formulation development and CMC activities by enabling remote experiment design, automated execution, and delivery of experimental datasets through a web portal.
Published Jul 31, 2026
| Starting Price | Not published (custom, fee-for-service) | Not published (quote-based CDMO) | Not published (quote-based CDMO) |
| Best For | Organizations seeking high-throughput, automation-first formulation screening with remote execution; emphasis on LAI/extended-release formulations | Organizations seeking large-scale integrated drug product development and manufacturing with global GMP infrastructure | Organizations needing broad formulation and enabling technologies across dosage forms with integrated development and manufacturing options |
| Key Strength | Remote robotic execution and data-driven workflows for parallel formulation screening; small-scale material requirements for miniaturized testing as stated by the company | Scale, established GMP systems, broad modality support, global facilities | Breadth of development technologies and integrated services across many dosage forms and stages |
| Key Weakness | Limited independent public proof points, early-stage organizational risk, security/compliance documentation not fully public, pricing opacity | Potentially less flexible for rapid early ideation compared with specialized high-throughput platforms; larger-provider overhead | May operate more as a programmatic CDMO rather than an immediate rapid-iteration lab partner; larger-provider overhead |
—
Where Persist AI may be a suitable option:
Where larger CDMOs often provide advantages:
Adoption trends / market signal: the company's seed and later-stage financings and accelerator participation indicate investor interest in the model but do not substitute for operational maturity or independent customer references.